Trial
NCT04550442
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI); Genentech, Inc.
Condition
Recurrent Chronic Myelomonocytic Leukemia
Intervention
Azacitidine
Why stopped
\<75% participation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-05